PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...

In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2 ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease marked by the thickening and scarring of lung tissue with unclear etiology. Affecting around five million people worldwide ...

University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ...